<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893045</url>
  </required_header>
  <id_info>
    <org_study_id>AMAG-FER-IDA-352</org_study_id>
    <nct_id>NCT03893045</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric
      subjects (2 years to &lt;18 years of age) with IDA, or felt by their clinician to be at risk of
      developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology,
      except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol
      protocol).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized to treatment in a 2:1 ratio (ferumoxytol: iron sucrose) and
      stratified by age group (2 to &lt;6 years; 6 to &lt;12 years; and 12 to &lt;18 years). Subjects will
      receive one of the following treatment regimens:

      • Ferumoxytol: 7 mg Fe/kg IV (maximum 510 mg/dose) x 2 doses, the first dose administered on
      Day 1 and the second 2 to 8 days later.

      OR

      • Iron sucrose (Venofer®): 4 mg Fe/kg IV (maximum 200 mg/dose) x 5 doses, the first dose on
      Day 1 and subsequent doses administered at least once per week and up to 3 times/week. All
      subjects will be monitored at the study site through at least 1 hour after the completion of
      each infusion of study drug. Assessment of blood Hgb concentrations, adverse events, and
      other safety assessments will be performed through study Week 5.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin from Baseline to Week 5</measure>
    <time_frame>35 days</time_frame>
    <description>Proportion of subjects achieving a change in hemoglobin from Baseline to Week 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>49 days</time_frame>
    <description>Incidence of Treatment Emergent Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of special interest (AESI)</measure>
    <time_frame>49 days</time_frame>
    <description>Incidence of adverse events of special interest (AESI) (hypotension and hypersensitivity)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: Area Under the Curve (AUC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clearance</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: Clearance</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: Distribution</description>
  </other_outcome>
  <other_outcome>
    <measure>Elimination half-lives</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: Elimination half-lives</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferumoxytol</intervention_name>
    <description>Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <other_name>Feraheme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).</description>
    <arm_group_label>Iron sucrose</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 2 years to &lt;18 years of age at time of consent

          2. Has IDA defined as:

               1. Hemoglobin (Hgb) &lt;11.0 g/dL AND

               2. Any one or more of the following:

                    -  Transferrin saturation (TSAT) &lt;20%

                    -  ferritin &lt;100 ng/mL

          3. Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be
             tolerated, or for whom oral iron is considered medically inappropriate

        Exclusion Criteria:

          1. Known hypersensitivity reaction to any component of ferumoxytol or iron sucrose

          2. History of allergy to intravenous (IV) iron

          3. History of ≥2 clinically significant drug allergies

          4. Subjects with CKD (defined as eGFR of &lt;60 mL/min/1.73 m2 or a requirement for chronic
             hemodialysis or peritoneal dialysis during Screening)

          5. Low systolic blood pressure (BP) (age 1 to 9 years &lt;70 + [age in years x 2] mmHg, age
             10 to 17 years &lt;90 mmHg)

          6. Hgb ≤7.0 g/dL

          7. Serum ferritin level &gt;600 ng/mL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Interest</last_name>
    <phone>1-877-233-4781</phone>
    <email>AMAGCT@druginfo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimus U Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biomedical Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gwinnett Research Institute</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC Saules seimos medicinos centras</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipeda Children's Hospital</name>
      <address>
        <city>Klaipėda</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital-Affiliate of Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osrodek Badan Klinicznych In Vivo sp. z o.o.</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski Dr N. med. Jerzy Brzostek</name>
      <address>
        <city>Debica</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pro Familia Altera Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korczowski Bartosz, Gabinet Lekarski</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia MDM</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDA</keyword>
  <keyword>anemia</keyword>
  <keyword>pediatrics</keyword>
  <keyword>ferumoxytol</keyword>
  <keyword>iron sucrose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

